Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 2/20 | 0.44 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7854100 | 0.85 | MEN1 (0.44) | BRPF1EPHX2TAAR1HSD17B3BRD4 | |
| SCHEMBL6450576 | 0.83 | BRPF1 (0.44) | BRPF1EPHX2HSD17B3BRD4ALOX12 | |
| SCHEMBL8091908 | 0.82 | BRPF1 (0.41) | BRPF1GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL4793671 | 0.81 | BRD4 (0.41) | GRIA2BRPF1EPHX2HSD17B3BRD4 | |
| SCHEMBL1645852 | 0.80 | BRPF1 (0.38) | BRPF1EPHX2HSD17B3BRD4ALOX12 | |
| SCHEMBL9038711 | 0.79 | CES1 (0.44) | BRPF1MEN1KMT2AALDH1A1 | |
| SCHEMBL5232142 | 0.78 | MAPT (0.42) | GRIA2BRPF1BRD4GAAMEN1 | |
| SCHEMBL9304274 | 0.77 | EPHX2 (0.57) | EPHX2BRD4ALOX12KMT2AALDH1A1 | |
| SCHEMBL7544166 | 0.77 | GAA (0.42) | GRIA2BRPF1EPHX2GAAMEN1 | |
| SCHEMBL10680826 | 0.77 | BRPF1 (0.40) | BRPF1EPHX2HSD17B3BRD4ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019179515-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | 北京泰德制药股份有限公司 | 2019-09-26 | — | — | WO | disclosed |
| WO-2019161781-A1 | RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USAGE THEREOF | 北京泰德制药股份有限公司 | 2019-08-29 | — | — | WO | disclosed |
| US-20180212158-A1 | ORGANIC LIGHT-EMITTING DIODE MATERIALS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2018-07-26 | — | — | US | disclosed |
| US-8309537-B2 | Compositions and methods for treating colitis | AERPIO THERAPEUTICS INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110112055-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-7205306-B2 | Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-5015473-A | Beta-lactamase inhibitors | PFIZER INC. (US) | 1991-05-14 | — | — | US | disclosed |
| US-4826833-A | ANTIBIOTICS | PFIZER INC. (US) | 1989-05-02 | — | — | US | disclosed |
| EP-0097720-B1 | PROCESS FOR PREPARING SILVER HALIDE EMULSION | KONICA CORPORATION (JP) | 1986-11-26 | — | — | EP | disclosed |
| EP-0097720-A1 | PROCESS FOR PREPARING SILVER HALIDE EMULSION | KONICA CORPORATION (JP) | 1984-01-11 | — | — | EP | disclosed |
| US-4307185-A | SENSITIZING DYE OF CYANINE STRUCTURE | FUJI PHOTO FILM CO., LTD. (JP) | 1981-12-22 | — | — | US | disclosed |
| US-4268620-A | Method of processing of light-sensitive silver halide photographic material | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1981-05-19 | — | — | US | disclosed |
| US-4001020-A | DEVELOPING A SILVER HA1IDE EMULSION IN CONTACT WITH A HETEROCYCLIC THIONE AND A POLYALKYLENE OXIDE | FUJI PHOTO FILM CO., LTD. (JA) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112055-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | ALPI, SI, SLC10A2 | GRIA2 1994/4885BRPF1 3419/4885EPHX2 472/4885 |
| US-20180212158-A1 | ORGANIC LIGHT-EMITTING DIODE MATERIALS | MSN, DDT, NECTIN4 | GRIA2 2150/4885BRPF1 1786/4885EPHX2 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.